MARKET

NLTX

NLTX

Neoleukin Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.43
-0.28
-2.61%
Opening 14:10 02/20 EST
OPEN
10.69
PREV CLOSE
10.71
HIGH
10.87
LOW
10.07
VOLUME
144.33K
TURNOVER
--
52 WEEK HIGH
13.71
52 WEEK LOW
2.190
MARKET CAP
507.14M
P/E (TTM)
-4.0747
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NLTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NLTX News

  • Benzinga's Top Upgrades, Downgrades For February 18, 2020
  • Benzinga.2d ago
  • Citigroup sees 36% upside in Amarin in premarket analyst action
  • Seeking Alpha - Article.2d ago
  • Guggenheim Securities Initiates Coverage On Neoleukin Therapeutics with Buy Rating, Announces $20 Price Target
  • Benzinga.2d ago
  • Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks Idea Forum | Oncology Day
  • GlobeNewswire.02/06 13:00

More

Industry

Biotechnology & Medical Research
-0.24%
Pharmaceuticals & Medical Research
-0.59%

Hot Stocks

Name
Price
%Change

About NLTX

Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.
More

Webull offers Neoleukin Therapeutics Inc (NLTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.